Biopartnering Seminar Series

Martin Latour
Tuesday, March 28, 2017 - 6:30pm

Interactive Discussion in the role of an MSL and MA within a Medical Affairs Department in Pharma - Martin Latour, Medical Advisor, BioTherapeutics & Cross-Therapeutics, Department of Medical Affairs, AbbVie Canada

Abstract: 
The objective of this presentation will be to provide an overall description of the MA/MSL in terms of their roles/requirements within a given pharma organization.

I will go over the diversified training requirements, key personal-attributes and traits such as their scientific integrity, flexibility with external stakeholders and Key Opinion Leaders (KOL).

In addition, there will be an open discussion on their constant requirement for agility, accountability and business acumen needed to navigate well within the cross-functional teams of pharma organizations.

Bio:
Medical Affairs roles as a Medical Advisor (MA) and Medical Science Liaison (MSL) in the pharmaceutical industry. Senior scientist with a post-doc in pharmacology from the University of Manitoba in liver pharmacology studying insulin sensitivity in pre-clinical models. PhD in exercise physiology with close interests in liver metabolism and hormonal regulation during prolonged exercise in rodents. Current scientific interests in autoimmune diseases (Gastroenterology - Inflammatory Bowel Diseases (IBD), Dermatology & Rheumatology), immunology, diabetes, metabolic syndrome, respiratory diseases and overactive bladder.

Current Role:
Medical Advisor - Biotherapeutics and Cross-Therapeutics Lead AbbVie Canada for the past 2 years, I am the key medical resource for internal and external stakeholders to meet scientific education needs and data generation requirements in biotherapeutics. Work cross functionally, help develop, align and execute the Biotherapeutics strategy on scientific education for the different stakeholders.

Recent Past role:
Medical Science Liaison (MSL) Gastroenterology / Immunology / Inflammatory Bowel Diseases (IBD) AbbVie Canada for a year before the MA BioT position. As an MSL, I closely interacted with external experts in Gastroenterology for the adalimumab (Humira) indications of Crohn's Disease (CD) and Ulcerative Colitis (UC). I identified clinic research sites for the post-marketing observational studies conducted by AbbVie and supported, and executed educational and advisory programs.